Minerva Neurosciences Inc is a Minerva Neurosciences Inc is a clinical-stage biopharmaceutical company.
Minerva Neurosciences Inc (NERV) had a rough trading day for Tuesday November 24 as shares tumbled 5.34%, or a loss of $-0.21 per share, to close at $3.72. After opening the day at $3.97, shares of Minerva Neurosciences Inc traded as high as $4.00 and as low as $3.65. Volume was 693,455 shares over 3,512 trades, against an average daily volume of n/a shares and a total float of 42.67 million.
As a result of the decline, Minerva Neurosciences Inc now has a market cap of $158.75 million. In the last year, shares of Minerva Neurosciences Inc have traded between a range of $15.22 and $1.81, and its 50-day SMA is currently $n/a and 200-day SMA is $n/a.
Minerva Neurosciences Inc is a clinical-stage biopharmaceutical company. The company primarily focuses on the development and commercialization of a portfolio of product candidates to treat patients suffering from central nervous system diseases. Targeted disorders include schizophrenia, insomnia, major depressive disorder and Parkinson’s disease. Its product portfolio and potential indications include Roluperidone for the treatment of negative symptoms in patients with schizophrenia; Seltorexant, for the treatment of insomnia disorder and major depressive disorder; MIN-117 for the treatment of MDD; and MIN-301 for the treatment of Parkinson’s disease.
Minerva Neurosciences Inc is based out of Waltham, MA and has some 14 employees. Its CEO is Remy Luthringer.